A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Cisplatin; Gemcitabine
Indications Bladder cancer; Prostate cancer; Renal cancer; Urethral cancer; Urogenital cancer
Focus Therapeutic Use

03 Aug 2022 Status changed from active, no longer recruiting to completed.
07 Jun 2022 Results assessing association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 presented at the 58th Annual Meeting of the American Society of Clinical Oncology
07 Jun 2022 Results assessing association of DNA damage repair (DDR) mutations (mts) and clinical outcomes presented at the 58th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com